Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients

Key facts

Sponsor

GenSight Biologics

Principal Investigator

CATHERINE J. VIGNAL, MD

CIC CHNO DES QUINZE VINGTS

Intervention

GS010(genetic)

Enrollment

19 enrolled

Eligibility

18 years · All sexes

Timeline

2014 – 2020

Study locations (1)

• CIC du CHNO DES QUINZE-VINGTS, Paris, France

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Leber hereditary optic neuropathy

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE3NCT07406854
  A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation
  Wuhan Neurophth Biotechnology Limited Company
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05293626
  Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations
  Neurophth Therapeutics Inc
• RECRUITINGNANCT06682819
  Metabolomics Analysis According to the Retinal Nerve Fiber Layer in Patients With NOHL Mutations (MétabOCT)
  Hôpital Necker-Enfants Malades
• ENROLLING BY INVITATIONNCT06376279
  Genetic Diagnosis in Inborn Errors of Metabolism
  Region Stockholm

See all trials for Leber hereditary optic neuropathy →